Hb-egf gene therapy for diabetes
AssigneeKagoshima University
InventorsKen-ichiro KOSAI, Eriko MATSUDA
Life of this patent
Estimating the term…
Abstract
The present invention provides a novel therapeutic means that is relatively low invasive and capable of exerting a desired therapeutic effect on diabetes including T1D. Specifically, an agent for protecting and/or regenerating a pancreatic β cell in a mammal with diabetes is provided, which contains a nucleic acid encoding a heparin-binding epidermal growth factor-like growth factor (HB-EGF), wherein the agent is systemically administered. The aforementioned preparation in combination with a nucleic acid encoding hepatocyte growth factor (HGF) is also provided.
Claims11
-10. (canceled)
A method of treating diabetes in a mammal comprising systemically administering to the mammal an effective amount of a nucleic acid encoding a heparin-binding epidermal growth factor-like growth factor (HB-EGF).
The method according to claim 1, wherein the nucleic acid is carried on a viral vector.
Dependencies are inferred from the claim text.